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Abstract
In an age of expanded genetic screening, fragile X syndrome is increasingly consid-
ered a candidate condition, given its prevalence, the absence of curative interven-
tions, and its impact on families. However, relatively little research has explored 
the views of families and people living with fragile X syndrome toward population 
screening. This study reports on in-depth interviews with 19 participants: 3 with 
people diagnosed with a fragile X condition (fragile X syndrome = 2, FXTAS = 1) 
and 16 people with fragile X syndrome in their family (11 parents, 2 grandparents, 
1 spouse, 1 sibling, and 1 aunt) living in the UK. This study reveals the complex-
ity of attitudes within this group and the existence of genuine ambivalence toward 
different population screening programs. While the overwhelming majority believed 
that preconception and newborn genetic screening should be made available to the 
general public, the notion of prenatal screening was far more controversial, with only 
five participants expressing support for such a program. Expressivist concerns were 
highlighted equally both by those who supported prenatal screening, as by also those 
who did not. Participants who supported prenatal screening drew clear distinctions 
between people with fragile X syndrome and the condition itself, in order to neutral-
ize expressivist concerns and existential threat. However, for others, this division was 
challenging to maintain. Impairment effects associated with fragile X syndrome, more 
specifically, its implications for behavior, intellect, and personality, made it harder 
for some participants to conceptually separate the person from their condition. This 
study concludes that screening remains a complex issue for families living with ge-
netic conditions and that expressivist concerns affect, and are managed by, families 
living with different types of disability in contrasting ways. Screening for conditions 
that affect personality, behavior, and intellect produces unique iterations of expres-
sivism, identity, and stigmatization that families produce specific, and creative, strat-
egies to navigate.
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1  | INTRODUC TION
Fragile X syndrome is the leading cause of inherited intellectual 
disability worldwide (Johansen Tab er et al., 2019). An estimated 
1 in 291 women in western countries carry the FMR1 premuta-
tion that causes fragile X syndrome (Hunter et al., 2014). Given 
the significant impact fragile X syndrome has on families, to-
gether with the lack of curative treatment, the FMR1 premutation 
is considered a prime candidate for population-based screening 
programs (preconception/prenatal/newborn) internationally (Hill 
et al., 2010).
Rapid developments in the world of genomic medicine over 
the past ten years, including the integration of whole-genome se-
quencing into state funded/subsidized healthcare systems, such 
as the NHS (National Health Service), now mean that expanded 
genomic screening programs at population level are—at least tech-
nologically—feasible. Australia and the Netherlands, for example, 
have introduced pilots of large-scale pre-conceptual genetic carrier 
screening programs in recent years (Mackenzie’s Mission, 2020; 
University Medical Centre Groningen, 2016), and such screening 
programs appear set to proliferate on a global scale.
While expanded genetic screening of the general public is pre-
mised on a desire to extend reproductive autonomy and the (cur-
rently limited) range of reproductive options available to carrier 
couples/individuals, decisions around which conditions should be in-
cluded on carrier panels, and the point in the reproductive pathway 
such screening should be delivered (e.g., preconception, prenatal), 
are controversial (Kirk et al., 2020).
Critics of expanded screening programs have highlighted that 
there may be costs of genomic screening programs to families cur-
rently living with genetic conditions. This may be in the form of 
decreased availability of resources, for example, research into treat-
ments, or social consequences, such as stigma (Kellogg et al., 2014). 
The transformation of a rare genetic condition into a ‘screened-for’ 
condition has also been demonstrated to change its public profile, in-
troducing new ideas about risk to prospective parents, and account-
ability to those with already affected children. There is evidence, for 
example, of the felt need among parents of children with Down syn-
drome, to ‘justify’ their child's existence in light of universal antena-
tal screening technologies for the condition (Cohen, 2019). Indeed, 
the potential of these technologies, and the practices that surround 
them, to ‘express’, or propagate, a negative appraisal of the value 
of life with disabling traits is at the heart of debates around the so-
called ‘expressivist objection’ (Parens & Asch, 1999). The ‘expres-
sivist objection’ was an argument originally developed to highlight 
the negative value assigned to disability inherent in prenatal testing 
and selective termination practices (Buchanan, 1996). However, use 
of the concept has since been extended to highlight examples of 
‘expressivism’ as they relate to other forms of genetic technologies. 
Indeed, in recent years, accumulating evidence suggests that the con-
cept is relevant to a wide range of current (McNeill et al., 2019), and 
emerging, reprogenetic practices (Hoffman-Andrews et al., 2019), 
and has a substantial impact on the views and decisions of people 
living with genetic and screened-for conditions (Boardman, 2014; 
Boardman & Hale, 2018).
Despite this range of impacts on affected families, studies ex-
ploring the social/ethical acceptability of genomic screening have 
largely focused analytic attention on the views of the general public 
toward screening (Anido et al., 2007; Fanos et al., 2006; Metcalfe 
et al., 2017; Ryynänen et al., 1999), with a smaller body of work ad-
dressing the views of affected families (Archibald et al., 2013; Bailey 
et al, 2012; Skinner et al., 2003). While an exploration of public at-
titudes is clearly essential as the intended recipients of screening, 
families living with genetic conditions possess direct, and intimate, 
experience of the condition in question that is of relevance to both 
the design of screening programs (e.g., determining the conditions 
are to be included) and their implementation (informing the deci-
sion-making of those screened). The need for consultation with, and 
an exploration of the views of such families, is therefore paramount 
in any evaluation of the harms and benefits of future screening 
programs.
In light of these arguments, this study takes the experiences 
and views of families and individuals living with fragile X syndrome, 
as a point of departure through which to explore the acceptability 
of three different types of population screening program for frag-
ile X syndrome in the UK (preconception, prenatal, and newborn). 
Using in-depth qualitative data with people diagnosed with fragile 
X conditions (n = 3) and their family members (n = 16), this paper 
highlights the hopes, concerns, and expectations around screening 
for those who know fragile X syndrome intimately. It will outline 
the tensions that emerge within participants’ accounts of screen-
ing, particularly as they relate to their lived experiences, personal 
identity negotiations, expressivism, and stigma, as well as the strate-
gies participants employ to defuse and neutralize them. Through so 
doing, this paper contributes to an emerging literature exploring the 
views of people with genetic conditions toward the ever-expanding 
world of genomic medicine (Boardman & Hale, 2018), and the role 
What is known on this topic
People with genetic conditions should be considered in 
assessments of population genetic screening, yet are not 
always consulted. What research has been done has shown 
support for screening, although conflicts emerge around 
the ‘expressivist objection’ and the disvaluing of family 
members through screening support.
What this paper adds to the topic
Families living with fragile X syndrome generally sup-
port population screening, but with some ambivalence. 
Intellectual disability produces unique iterations of the 
dilemmas that face all families living with genetic disease 
considering population screening, and families develop 
creative strategies to navigate them.
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of impairment experiences (i.e., experiences of the impacts of the 
condition, as separate to the socially created ‘disability’ therein.
1.1 | Fragile X syndrome
Fragile X syndrome is the leading cause of inherited intellectual dis-
ability worldwide and the second most common cause of intellec-
tual disability after Down syndrome (Dykens et al., 2000). Fragile X 
syndrome results from a CGC repeat in the 5′ untranslated region of 
the FMR1 gene and affects approximately 1 in 4,000 males and 1 in 
6,000 females.
Individuals with the full mutation (pathogenic variant), that is, 
those who have over 200 repeats, have fragile X syndrome, which 
presents as learning difficulties as well as social, behavioral, and 
emotional difficulties (including ADHD and autism). In addition to 
these symptoms, fragile X syndrome is sometimes associated with 
epilepsy as well as mildly dysmorphic facial features.
Males are typically more severely affected than females with frag-
ile X syndrome, with some females exhibiting no clinical symptoms 
at all. Despite onset of symptoms from approximately 9–12 months 
of age, the average age at diagnosis is around 36 months, although 
can be much later (Bailey et al., 2009). Diagnostic delays are often 
cited as the reason that an estimated 29% of affected families go 
on to have a second child with fragile X syndrome before the first 
child is diagnosed, and is a significant argument used in favor of new-
born screening (Bailey et al., 2009). While no curative treatment for 
fragile X syndrome currently exists, various interventions (includ-
ing behavioral interventions, medication, speech, and occupational 
therapies, as well as family support) are available to help manage the 
condition (Hagerman et al., 2009).
1.2 | Inheritance of fragile X syndrome
Fragile X syndrome is inherited in an X-linked dominant pattern, as 
the mutation is located on the X chromosome. Both males and fe-
males can be carriers of the fragile X premutation (between 55 and 
200 repeats); however, only females can transmit fragile X syndrome 
to their offspring. Male carriers of the fragile X premutation do not 
transmit fragile X syndrome; however, each of their daughters will 
receive the fragile X premutation (and as such may have children 
with fragile X syndrome themselves).
Unlike most other genetic conditions whereby carrier status is 
a relatively benign condition, the fragile X premutation is associ-
ated with two distinct conditions. In women, the fragile X premu-
tation can cause fragile X-associated primary ovarian insufficiency 
(FXPOI), causing irregular menstruation, reduced fertility, and early 
menopause. Male premutation carriers (and to a lesser extent, fe-
males) can experience fragile X-associated tremor/ataxia (FXTAS) 
which onsets later in life (typically 50 s/60 s), causing difficulties with 
motor control, coordination, memory and cognition (Wheeler et al., 
2017). It has been estimated that approximately 20%–30% of male 
carriers of the fragile X premutation develop FXTAS, and approx-
imately 20%–25% of female premutation carriers develop FXPOI 
(Jacquemont et al., 2004).
1.3 | Screening acceptability for fragile X syndrome
Screening policies for fragile X syndrome vary internationally. Pilot 
studies have been conducted with women of reproductive age 
(Archibald et al., 2009; Metcalfe et al., 2008), pregnant women 
(Cronister et al., 2005; Hung et al., 2019) and newborn babies 
(Okoniewski et al., 2019; Saul et al., 2008). However, the lack of 
curative treatment proves a barrier to screening implementation in 
many countries. Furthermore, the wide spectrum of severities as-
sociated with fragile X syndrome makes the provision of an accu-
rate prognosis following screening extremely challenging for genetic 
counselors and potentially reduces the utility of the information 
for parents. Given this complexity, as well as concerns around the 
screening test itself, no population screening program for fragile X 
syndrome currently exists in the UK.
A key consideration in the evaluation of screening programs 
worldwide is the acceptability of that program (Dimmock, 2017). 
As such, various studies have been conducted exploring attitudes 
to screening among key stakeholder groups. These have included 
healthcare professionals (Aacharya & Schindler, 2013), women from 
the general population (Archibald et al., 2013; Metcalfe et al., 2008), 
parents of newborn babies (Skinner et al., 2011), premutation carrier 
women identified through screening (Anido et al., 2007), and par-
ents/relatives of children with fragile X syndrome (Bailey et al, 2012; 
Skinner et al., 2003).
While these studies provide a useful overview of the perceptions 
of a wide variety of stakeholders, no studies thus far have included 
the views of people living with fragile X syndrome, FXTAS, or FXPOI 
themselves.
This study, using in-depth individual interviews, incorporates the 
views of people living with fragile X conditions themselves (n = 3), 
as well as their family members (n = 16), and explores attitudes to-
ward preconception, prenatal, and newborn screening for fragile X 
syndrome.
2  | MATERIAL S AND METHODS
The data for this study were gathered as part of a larger mixed meth-
ods study exploring attitudes to genetic screening among families 
living with a range of genetic conditions. All data were gathered 
February 2017–March 2018.
2.1 | Participants
Interview participants for this study were recruited through three 
separate calls placed in the Fragile X Society UK e-newsletter at 
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four monthly intervals. The call was also posted on the ‘research’ 
section of their website. In addition, families who had a registered 
interest in participating in fragile X-related research through the 
Patrick Wilde Centre (a UK research center for fragile X condi-
tions) were contacted via email about the research. Participants 
were eligible for interview if they were aged over 18, living in the 
UK, were English speaking and either had a fragile X condition 
themselves, or had a family member with a fragile X condition (in-
cluding FXTAS and FXPOI). The definition of family member was 
kept deliberately broad to include extended family members as 
well as non-biological family members such as step and adopted 
relatives.
The advertisements led to responses from 20 people, and 17 
interviews were successfully completed with 19 different partic-
ipants (two joint interviews were conducted, one with a mother 
and her son with fragile X syndrome, and another with a couple—
Table 1). Two people who initially indicated their willingness to 
participate failed to respond to attempts to arrange an interview, 
and one person was excluded as they did not meet the eligibility 
criteria. Given the relatively low numbers of people with fragile X 
syndrome in the sample (n = 3), snowball sampling was attempted 
through already recruited relatives; however, this strategy was ul-
timately unsuccessful as most thought an interview would be too 
taxing for their family member.
2.2 | Interviews
The interview schedule was developed around one previously im-
plemented for families living with genetic conditions considering 
screening (Boardman et al., 2019, 2020; Boardman & Hale, 2018), 
and adapted for this population. The questions were passed 
through an advisory group made up of four fragile X society staff 
members (including a clinician), and was piloted with a volunteer 
parent.
Seventeen interviews were successfully completed using a 
range of different techniques to suit participant needs and pref-
erences. These included face-to-face interviewing (n = 3), tele-
phone interviewing (n = 13), and email interviewing (n = 1). Email 
interviewing, while lacking the visual and audio cues and sense 
of rapport that can be developed through face-to-face or tele-
phone interviewing, enabled the inclusion of a person with fragile 
X syndrome (Holly), whose social anxiety would have otherwise 
precluded her participation. Interviews were designed to explore 
experiences of life with fragile X conditions within families, views 
and experiences of reproduction and genetic risk and participants 
were also directly asked to reflect on their perceptions of popula-
tion screening. As fragile X syndrome is associated with learning 
difficulties and social anxieties, participation in the research for 
affected individuals was supported through inclusive interview 
techniques. These ranged from adapting the method of interview 
to allow for digital interviewing, speaking to family members be-
fore the interview to gauge the participant's communication and 
comprehension needs and adapting the interview questions in line 
with these (Barter et al., 2017). For one participant with fragile X 
syndrome, the interview was conducted with a caregiver present 
who was able to translate the research questions into everyday 
scenarios that the participant could more easily relate to, for ex-
ample, by referring to genetic testing that had already occurred 
within their own family. These approaches enabled two people 
with fragile X syndrome (a 17-year-old male and a 26-year-old fe-
male) to contribute their perspectives to the research.
While participants were recruited through the fragile X society, 
the interviews were all conducted by a white female qualitative re-
searcher, with whom the participants were previously unfamiliar. 
This unfamiliarity may have prevented the recruitment of further 
participants with fragile X syndrome (given the condition's associa-
tion with social anxiety) than if the interviews had been conducted 
by a familiar support group staff member. However, the separation 
of the research project from the group may have also afforded the 
participants greater anonymity, and sense of accountability to the 
group.
Given the method of recruitment and the possibility of par-
ticipants being known to one another, particular care was taken 
to protect the anonymity of those who were involved. After the 
interviews had been transcribed verbatim, all identifying informa-
tion was removed from the transcripts and the participants were 
assigned pseudonyms. Where segments of participants’ stories 
could not easily be anonymized (e.g., because they were partic-
ularly well known within the group), they were either omitted, or 
‘participant disguising’ techniques (Weiss, 1994) (e.g., the altering 
of ages and/or genders) were employed where this would not sub-
stantially distort the content, and the emerging themes, of their 
story. All participants were provided with a copy of their de-iden-
tified transcript for checking, although in reality, only three took 
up this opportunity.
2.3 | Data analysis
The data were analyzed using Nvivo 11 software, and a constructiv-
ist approach to grounded data analysis was used. This process was 
inductive, allowing the themes to emerge directly from the research 
data, although unlike traditional grounded theory analysis, the lit-
erature was consulted throughout the analysis process to facilitate 
theme refinement. After initial ‘open coding’, higher level hierarchi-
cal coding was undertaken. A repeated process of coding, refine-
ment of concepts (through data interpretation and insights from the 
surrounding literature), and re-coding was completed over a period 
of three months until data saturation had occurred (i.e., no new con-
cepts were emerging and all of the data were included within the 
final coding framework) (Glaser & Strauss, 1967).
Upon completion of coding, participant transcripts were assigned 
quantitative categories according to their support, or non-support, for 
the three screening programs (Table 1). Initially, three categories were 
used to categorize participants (support/non-support/ambivalent); 
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TA B L E  1   Participant pseudonym, gender, age, relationship to fragile X syndrome, and attitudes toward screening
No. Name Gender Age Relationship to fragile X








1 Malcolm M 56 Parent of 23-year-old son with 
FXS and unaffected daughter 
(donor conception)
None known ✓✓ ✓✓ ✓✓
2 Judy F 51 Parent of 23-year-old son with 
FXS and unaffected daughter 
(donor conception). Wife of 
Malcolm
Cousin has FXS. Father has 
premutation
✓ ✓✓ XX
3 Mary F 75 Spouse has FXTAS Brother has FXS. Step-
granddaughter with FXS
✓✓ XX ✓✓
4 Sue F 74 Has FXTAS Sister has FXTAS. Has two 
grandsons with FXS
✓✓ X ✓✓
5 Ali F 48 Premutation carrier, 2 unaffected 
daughters
One nephew and two 
nieces with FXS
✓ XX ✓
6 Elisabete F 31 Mother of 3-year-old boy with 
FXS and unaffected daughter 
(prenatal testing)
None known ✓ ✓✓ XX
7 Emma F 34 Mother of 14-year-old boy with 
FXS and unaffected daughter 
(PGD)
Sister premutation carrier ✓✓ ✓✓ XX
8 Luca M 17 Has FXS Grandfather has FXTAS ✓✓ XX ✓✓
9 Chiara F 43 Mother of Luca (with FXS). Also 
has unaffected son (no prenatal 
testing)
Father has FXTAS. First 
cousin once removed has 
FXS
✓ XX ✓✓
10 Joanne F 47 Mother of two daughters with 
FXS (15, 12)
Sister has son with FXS ✓✓ XX ✓
11 Valerie F 66 Mother of son (33) and daughter 
(29) both with FXS (no prenatal 
testing)
Cousin with FXTAS and 
daughter with FXS
✓✓ XX ✓
12 Jane F 58 Mother of son (25) and 
daughter (23) both with FXS. 
Also unaffected son (20) and 
daughter (19)(no prenatal 
testing)
Grandson (son of daughter, 
23, with FXS) has FXS.
Sister has daughter with 
FXS.
First cousin once removed 




F 47 Mother of two daughters (15 
and 11) with FXS. (no prenatal 
testing)
Father has FXTAS.
Cousin has son with FXS
✓✓ XX ✓✓
14 Zoe F 40 Premutation carrier with carrier 
son (16) and unaffected 
daughter (12)
Two brothers with FXS ✓ XX ✓✓
15 Holly F 26 Has FXS Sister has FXS.
Two male cousins have FXS
✓✓ — ✓✓
16 Rachel F 38 Mother of boy (10) with FXS and 
unaffected boy (2) (no prenatal 
testing)
Father had FXTAS 
(deceased). Aunt and 
uncle both premutation 
carriers.
Six cousins all premutation 
carriers. Two cousins have 
sons with FXS and a third 
cousin currently pregnant 
with a boy with FXS
✓ XX ✓
17 Tony M 65 Grandparent of boy (7) with FXS None known ✓✓ — ✓✓
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however, this was eventually expanded to five categories to capture 
the complexity of attitudes across the dataset. The final categories 
were support, non-support, ambivalent support, ambivalent non-sup-
port, and neutral/unable to answer. The categories of ambivalent sup-
port and non-support were developed to capture the views of people 
who took a view on a screening program (support or non-support), 
but who also held considerable reservations, or contradictory feelings 
about the program. These categories enable a broad overview of the 
level of support, and its dispersion across the dataset.
This paper presents the core themes derived from the final 
coding framework of the qualitative analysis along with the quan-
titative categories. The data from all participants contributed to 
this final coding framework, irrespective of whether their excerpts 
are included in this paper. Excerpts have been selected that par-
ticularly clearly and eloquently represent the data coded to that 
theme.
3  | RESULTS
This section is organized around clusters of core themes emerging 
from the analysis as they related to the three different screening 
programs under study.
3.1 | Newborn screening: avoiding the odyssey or 
‘making a well-child sick’?
Life with fragile X syndrome was almost universally described by 
participants as a challenging experience, that typically involved a 
protracted and difficult journey to diagnosis. For the 11 parents of 
children with fragile X syndrome, the age at diagnosis ranged from 
2 to 8 years, averaging 4.5 years. This delay meant that parents 
were living with the effects of fragile X syndrome, without profes-
sional support, for several years. Six of these 11 parents went on to 
have further children during pre-diagnosis phase, with four (Joanne, 
Valerie, Jane, and Sally-Anne) having further children with fragile X 
syndrome.
For the majority of the parents (10/11), the long delay to diagnosis 
meant that it was experienced largely as a relief, and marked the end 
of the diagnostic odyssey that had plagued their early years with their 
child. Chiara, aged 43, recalled the diagnosis of her (now) 17-year-old 
son, Luca, with fragile X syndrome (at age six) in the following way:
…that was the hardest time [pre-diagnosis] for us. My 
husband and I were constantly blaming each other. 
We each thought the other wasn't doing enough for 
him… and the [extended] family back at home [in Italy] 
didn't believe it, they kept saying he'd grow out of it. 
We kept getting fobbed off by the paediatrician. So 
when Luca was finally diagnosed, it was this huge 
relief. It was saying that yes, we were dealing with 
something that was very hard, and no, I wasn't imag-
ining it, you know? I had a name for it and could reach 
out for help and…. that was very healing for us. 
(Chiara, supporter of newborn screening, mother of 
son with FXS)
For Chiara, the diagnosis of her son was a validating experience, 
absolving her and her husband's guilt for having ‘caused’ Luca's appar-
ent difficulties, and was a key reason she gave for supporting newborn 
screening. Having known earlier, Chiara believed, would have pre-
vented the strained interfamilial relationships that the lack of a clear 
diagnosis created, and prevented the feelings of isolation that had 
overshadowed her early parenting experiences.
While ten other participants supported Chiara's view that 
newborn screening was an important source of information, sup-
port, and validation, other participants were more ambivalent in 
their support (n = 5). Three participants did not support newborn 
screening at all.
Judy, for example, was the 51-year-old mother of David (now 23) 
who was diagnosed with fragile X syndrome at age seven. Judy de-
scribed David's diagnosis as a ‘traumatic’ event, as it was the point 
that she realized the permanence of David's difficulties. She de-
scribed the diagnosis as having a catastrophic impact on her imag-
ined future with her son, triggering a form of grief. Drawing on these 
experiences, Judy described her thoughts on newborn screening in 
the following way:
I think you'd be taking something away from them 
[parent and newborn], actually if you pick it up at 
birth. You're taking away the normality, when their 
baby's still absolutely fine…. like making a ‘well-child’ 
sick, really. It could really cause all sorts of bonding 
problems, I think, and that bond can already be a 
problem for these kids…you know, if I went under a 
bus tomorrow, David might ask where I was, but then 
No. Name Gender Age Relationship to fragile X








19 Kathryn F 37 Mother of son (4) with FXS 
(undergoing PGD)
Sister has daughter with 
FXS.
Cousin has son with FXS
✓✓ ✓✓ ✓✓
Note: ✓✓, support for screening; ✓, ambivalent support for screening; XX, non-support for screening; X, ambivalent non-support for screening; —, 
neutral/unable to take a view.
Abbreviations: FXS, Fragile X syndrome; FXTAS, Fragile X-associated tremor/ataxia syndrome; PGD, Pre-implantation Genetic Diagnosis.
TA B L E  1   (Continued)
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it would be ‘can I have a bag of crisps please?’… I cer-
tainly grieved the loss of David, the child I thought I 
had, because it was then [diagnosis] that I realised this 
was genetic and permanent…so I think it's better to 
know when you're pregnant to be honest, so at least 
you have a choice. If it [screening] isn't giving you op-
tions, what's the point? 
(Judy, non-supporter of newborn screening, mother 
of son with FXS)
Judy's account highlights the issues around newborn screening that 
were both generic—that it does not afford parents any additional repro-
ductive options as compared to other forms of screening—but that were 
also specific to the unique challenges posed by fragile X syndrome, of 
which bonding was key. While Chiara experienced her son's diagnosis 
as validation and as marking the end point of their diagnostic odyssey, 
Judy perceived a diagnosis in the pre-symptomatic phase of fragile X 
syndrome as an extension of the syndrome- as making a ‘well-child sick’.
Seven participants raised the possibility that newborn screening 
would offer reproductive choice in subsequent pregnancies for new 
parents. Although, for some, this knowledge was described as a dou-
ble-edged sword. Joanne was 47 at her interview, and the mother 
of two girls, Chloe (15) and Tess (12), both with fragile X syndrome. 
Chloe had not been diagnosed when Joanne became pregnant with 
Tess, so she was unaware of the possibility of recurrence. Reflecting 
on newborn screening, Joanne commented:
…In hindsight now I’m glad I didn't know that Tess 
[second child] might have it too. We had no idea 
it could happen again- we probably wouldn't have 
had her. Who knows? But what I do know is that not 
having Tess would have been a massive mistake, so 
I have mixed feelings about it, but I can see that it 
is important for other people to give them options 
for the next child, so yeah it's probably a good thing 
on balance. 
(Joanne, ambivalent supporter of newborn screening, 
mother of two daughters with FXS)
The idea that newborn screening could have altered the course of 
their reproductive trajectories and the composition of their families 
left participants such as Joanne with ambivalent feelings. The rhetoric 
of information as universally positive and empowering needed to be 
reconciled alongside the possibility that genetic risk information might 
have prevented their subsequent child's existence, irrespective of frag-
ile X status.
3.2 | Preconception screening: information, 
education, and stigma
Unlike newborn screening, preconception genetic screening gar-
nered support from all participants across the dataset (although 
eight expressed ambivalent support) and emerged as the most popu-
lar screening format. Rather than expanded reproductive autonomy, 
however, most participants positioned their support for preconcep-
tion screening in terms of information and education, as Holly, a 
26-year-old with fragile X syndrome commented:
I would say it's a good way to give people the knowl-
edge they need early on. Lack of awareness is a big 
problem, so the more people who know the better I 
would say. If you know early, you have time to find 
out a bit more about it and do your research and it's 
not a shock. 
(Holly, supporter of preconception screening, has 
FXS)
As well as informing the general public and raising awareness, 
preconception screening was also seen as a way that carriers could 
be alerted to the possibility of developing premature ovarian fail-
ure—a fact that participants felt was relevant to women's repro-
ductive planning. Ali is a 48-year-old carrier with two unaffected 
children. She discovered her premutation status following the diag-
nosis of all three of her sister's children with fragile X syndrome. Ali 
commented:
I think it's quite important that women know early 
on if they've got it [premutation], because if they 
want kids and they're one of them that gets infertil-
ity, they'll feel they've missed out …but on the other 
hand, it could also cause a lot of pressure if she hasn't 
got a partner yet, or a partner is put off. There's quite 
a stigma to it all, and it's a lot on that woman's shoul-
ders. I got off quite lightly really because I’m a car-
rier, but I didn't know, and I’ve had two healthy girls. 
So although I’m glad I didn't have to worry for noth-
ing, I still want both my girls tested when they're old 
enough- for their own health first and foremost. 
(Ali, ambivalent supporter of preconception screen-
ing, carrier)
The potential stigma and distress of discovering carrier status, 
which Ali perceived could become highly gendered in a preconcep-
tion screening context, had to be weighed up in Ali's mind against the 
potential health benefits she perceived for her daughters by identi-
fying their propensity to develop FXPOI or FXTAS later in life. Ali's 
acknowledgement of relief that she had not known her own status 
highlights the tensions inherent within this balancing act. Indeed, there 
was widespread evidence within the dataset of the shame, guilt and 
stigma that was associated with the transmission of fragile X through 
families, which participants discussed in the context of preconception 
screening.
Jane was 58 at the time of her interview and had five people in 
her family diagnosed with fragile X syndrome, including two of her 
four children, one grandchild, a niece, and a cousin. Her father, now 
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deceased, had been diagnosed with FXTAS. Jane described fragile X 
as being somewhat of a ‘shameful secret’ within her extended family, 
and one tinged with stigma, guilt, and blame. This, in turn, fed into 
her hopes and expectations of what preconception screening could 
deliver:
People in my family in past generations were either 
hidden away and you didn't speak about them, or 
they were put in institutions, which is awful. But per-
haps, you know, screening would open that up a bit, 
because I feel you owe it to your family members, if 
you're a carrier, to pass that information on, which 
doesn't always happen. I don't know why it's such a 
shameful secret. I know my dad did. It came from him 
originally, so I think he felt he had cursed this whole 
family. And I would hope that screening might start 
those conversations…if everyone is automatically 
screened. 
(Jane, supporter of preconception screening, mother 
of son and daughter with FXS)
For Jane, preconception carrier screening was seen as providing a 
means to enact one's ‘genetic responsibility’ (Etchegary et al., 2009)—
an obligation that she felt existed between biologically related kin, 
and yet was being mitigated against by stigma, guilt, and blame. The 
language of ‘curse’ shows how heavily entrenched the negative ideas 
about transmission were, exacerbated by the dominant inheritance of 
the condition and the identification of a single ‘original’ carrier within 
the family. Indeed, there was some evidence across the dataset that 
older generations, particularly grandparents, felt this more keenly, and 
took responsibility when the condition cascaded down subsequent 
generations of their family. By viewing screening as something that 
would eventually become accepted as routine, or ‘automatic’, Jane 
hoped that testing for the premutation could become detached from 
the familial guilt that currently overshadows it.
The stigmatization of fragile X, however, was not contained 
within affected families. Participants provided numerous exam-
ples of stigma that pervaded all aspects of their daily lives. As has 
been reported with other cases of ‘invisible disability’, such as au-
tism (Gray, 2002), participants felt that their children were being 
judged as ‘naughty’ (Emma) or ‘out of control’ (Moira) or that they 
were being judged as ‘bad parents’ (Malcolm) if their child became 
overwhelmed, behaved in unexpected ways, or had a ‘meltdown’ 
in public spaces. For some participants (Kathryn, Valerie), antic-
ipation of this stigma regularly prevented them from leaving the 
house.
For many participants, this awareness of the stigmatization of 
fragile X fed into their expectations of screening. Five participants re-
ported that while nearly all disability is stigmatized, that conditions 
involving learning/behavioral difficulties attract particularly height-
ened forms of stigmatization. Zoe (40) a premutation carrier with two 
brothers with fragile X syndrome commented:
I think personally think [preconception] screening will 
be really important to the public and people will want 
to have it, because look how many have the down 
syndrome screen. There's just less understanding of 
mental disability. People think they'll never be able 
to communicate, they'll always be dependent, they're 
violent, they'll be a burden, …as soon as they know 
it causes behavioural problems and things like that 
then, yes, they'll want to screen for it. People don't 
want kids with them problems, do they? 
(Zoe, ambivalent supporter of preconception screen-
ing, carrier)
Whereas Jane perceived that stigma could be a barrier to family 
communication about genetics, for Zoe, stigma was considered an 
impetus both for the introduction, but also the uptake, of population 
screening. Intellectual disability emerged as being marked out for very 
particular forms of stigmatization, separate to, and yet more intense 
than that assigned to physical disability.
3.3 | Prenatal screening: autonomy, 
expressivism, and identity
While preconception and newborn screening garnered broad sup-
port from most participants, the notion of prenatal screening was 
far more divisive due to its association with selective termination. 
Five participants stated that they would support a prenatal screen-
ing program, with the remainder of the participants (12) expressing 
non-support, or ambivalent, views. Two stated that they felt too 
conflicted to express a view at all. All of the participants (including 
those who supported prenatal screening) grappled with the per-
ceived contradiction between their desire to increase information 
and reproductive autonomy for the general population with the no-
tion that screening might have prevented their child's existence, and 
that it's very availability expresses disvalue of that existence. It is 
notable, however, that screening supporters and non-supporters re-
solved these conflicts in contrasting ways.
Kathryn, 37, had a four-year-old son, Jake, diagnosed with fragile 
X syndrome at the time of her interview (alone with two other chil-
dren diagnosed with the condition in her extended family), and was 
undergoing her second cycle of PGD. Kathryn explained her sup-
portive views toward prenatal screening, while also acknowledging 
expressivist concerns:
I think doing it [screening] prenatally is fine as long 
as….I think full information about the condition in all 
its forms is really important to make good decisions. 
As much as I find it upsetting, you have to remember 
this a disease you're getting rid of, not a person, and 
it's a disease that can be debilitating for the whole 
family. This is why we're currently in our second cycle 
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[of PGD] to stop… I mean, of course I wouldn't wish 
Jake away, I’d just…I’d wish his fragile X away. 
(Kathryn, ambivalent supporter of prenatal screen-
ing, mother of son with FXS)
Like the other four prenatal screening supporters, Kathryn indi-
cated the importance of high quality and unbiased information about 
all forms of fragile X syndrome as a vital resource to support any prena-
tal decision about the condition. While some participants who did not 
support prenatal screening queried whether the level of information 
required for ‘good’ decision-making was ever a realistic goal for the 
general population (Emma), screening supporters generally reported 
that a right to reproductive autonomy overrode concerns regarding 
how fully informed those decisions ultimately were. For Kathryn, the 
mother of a child with fragile X syndrome, expressivist concerns asso-
ciated with prenatal screening emerged as salient within her account. 
In order to manage them, Kathryn drew a clear ideological distinction 
between Jake himself, and fragile X syndrome. By so doing, Kathryn 
was able to clarify that the true target of selective reproductive prac-
tices was a ‘debilitating disease’ not a person, enabling her to deflect 
any critical appraisal of fragile X syndrome away from her son's life 
and consequently reconcile her view of screening with her support and 
love for her son.
However, for other participants, the distinction that Kathryn 
relied on—between a person and their condition—did not hold, 
particularly in the context of the unique impairment effects that 
were associated with fragile X syndrome. Rachel (38), the mother 
of a 10-year-old son, James, with fragile X syndrome and a second 
(unaffected) son (born without prenatal testing), felt that prenatal 
screening had eugenic undertones given the inseparability of people 
from their condition:
I think prenatal screening would ultimately be used 
as a way to get rid of people with fragile X syndrome, 
and I find that very hard to swallow. These kids have 
so much to offer and have as much right to be here 
as the next person. You know, with James, fragile X 
is part of his personality, his temperament, his inter-
ests, his behaviour. You can't think of it as something 
you can just get rid of and then you have a healthier 
version of your child… If I were to have James without 
it, would I even know who he was? It makes him who 
he is. 
(Rachel, non-supporter of prenatal screening, mother 
of son with FXS)
Unlike Kathryn, who conceptually separated out personhood from 
fragile X syndrome, Rachel viewed fragile X syndrome as so much a part 
of her son's existence that it could not be extracted. Whereas Kathryn 
had presented fragile X syndrome as a debilitating ‘disease’, Rachel 
conversely associated the fragile X mutation with positive characteris-
tics that she perceived to have been passed down through her family. 
Reflecting on her father's experience of FXTAS, she commented:
My dad was a really lovely person, no side to him, 
just so giving and loving, you know, and you see that 
in people with fragile X… Hopefully I'm a little bit 
like that too, as a carrier, and if I am, then that's the 
bit about me that I like. I think if you start trying to 
change things, you start screening for stuff, yes you 
might get rid of some of the problems, but you also 
lose the good bits as well. Very rarely is something 
100% completely bad. 
(Rachel, non-supporter of prenatal screening, mother 
of son with FXS)
While the genetic origin of familial diseases such as fragile X con-
ditions has been demonstrated to disrupt kinship relationships within 
families through the existence of blame, stigma, and guilt (e.g., Jane), 
Rachel's account conversely highlights how it could also be interpreted 
as affirming; confirming familial ties and integrating the genetic muta-
tion into a family legacy that consciously upheld the value of affected 
family members, while also deflecting the expressivist threats posed 
by prenatal screening.
4  | DISCUSSION
Overall, this paper presents the multi-faceted, and frequently am-
bivalent, attitudes of families living with fragile X syndrome toward 
three different types of population screening program: preconcep-
tion, prenatal, and newborn. Greatest support was shown overall for 
preconception screening, followed by newborn screening, whereas 
prenatal screening was far more divisive, confirming the findings of 
other studies in this area (Skinner et al., 2003; Bailey et al, 2012). 
However, the findings also highlight the range, and complexity, of 
the tensions that underpinned these participants’ screening support 
and non-support, as well as the ways they negotiated and resolved 
them. It is these tensions that may be missed by reliance on survey 
methods alone to explore screening attitudes. Yet, they are key to 
highlighting the wide range of factors that families living with ge-
netic conditions must navigate when considering population screen-
ing for the condition they live with.
The data, for example, starkly illuminate the role of impair-
ment, and impairment effects, in shaping the nature, and con-
tent, of the nuances around screening that emerged through 
participants’ responses to all three screening programs. Previous 
research on screening attitudes among families and individu-
als living with different types of genetic condition has revealed 
some common themes in their responses to screening. Research 
exploring the views of people and families living with conditions 
as diverse as spinal muscular atrophy (Boardman et al., 2017) and 
inherited retinol conditions (Hoffman-Andrews et al., 2019), for 
example, demonstrates that despite the wide spectrum of impair-
ment effects associated with these conditions, common themes 
can be identified. These themes include a querying of presumed 
low quality of life with genetic disease (Boardman & Hale, 2018; 
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Hoffman-Andrews et al., 2019), the role of social factors—nota-
bly stigma and environmental barriers—in shaping life experi-
ences (Boardman et al., 2020), the dire need for greater public 
awareness of the condition (Boardman & Hale, 2018), and the 
key role of expressivist concerns in framing screening responses 
(Hoffman-Andrews et al., 2019). Many of these core themes were 
also echoed in the accounts of families living with fragile X con-
ditions. However, this present study adds to this literature by also 
illuminating the unique iterations of stigma, identity politics, and 
expressivism that emerge within the screening attitudes of fami-
lies living with impairments that are associated with cognitive and 
behavioral differences, rather than those which are predominantly 
or entirely physical in presentation.
Positive attitudes toward newborn screening for fragile X syn-
drome have previously been identified in the literature (Bailey 
et al., 2012; Carmichael et al., 1999; Skinner et al., 2003) and were 
largely confirmed by this study. This support was largely driven by 
a desire to reduce uncertainty associated with the pre-diagnostic 
phase of the condition and, to a lesser extent, inform reproductive 
planning. However, the data also revealed concerns regarding the 
impact of an early diagnosis for families. The psychosocial effects of 
a newborn diagnosis in a pre-symptomatic infant have been noted 
in the wider literature on newborn screening, with implications for 
parental acceptance and adjustment to the condition (Grob, 2008), 
as well as the loss of enjoyment of the pre-symptomatic phase 
(Carmichael et al., 1999)—which may be as long as 12 months for 
fragile X syndrome. Three participants raised such concerns about 
newborn screening within this sample. Given the potential impact 
of fragile X syndrome on the development of affective bonds (de-
scribed vividly by Judy), the issue of parent/child relationship for-
mation after a newborn diagnosis might be more of a concern to this 
group than for other rare disease groups for which newborn screen-
ing is being considered.
Preconception screening was the program that garnered most 
support from participants, with the need to increase public infor-
mation and reproductive autonomy the key drivers behind this sup-
port. As has been acknowledged in the literature, however, there 
are many challenges associated with the implementation of precon-
ception screening; public knowledge of fragile X syndrome remains 
low (Archibald et al., 2013, 2016), and a lack of a family history with 
the condition is still a barrier to screening uptake, despite its irrele-
vance. This study adds that the stigmatization of conditions that in-
volve learning, behavioral, and cognitive differences, over those that 
are entirely physical, was perceived by participants to be both a key 
driver toward preconception screening uptake, yet also confirmed 
and reinforced through that screening. By transforming fragile X 
syndrome into a ‘screened-for’ condition, participants raised the 
possibility that the heightened stigma they perceived to be assigned 
to cognitive/intellectual disability, would be further underscored and 
left unchallenged. Indeed, public misunderstanding and ignorance of 
the impacts of fragile X syndrome punctuated the accounts of all the 
participants in this study, and underpinned much of their support 
for preconception screening, in the hope of raising awareness and 
understanding, as well as dispersing some of the shame and guilt 
experienced within fragile X affected families, particularly among 
older generations.
It is perhaps unsurprising—given its association with selective 
pregnancy termination—that prenatal screening emerged as the most 
controversial form of screening, and one which provoked the high-
est degree of ambivalence from participants, confirming the findings 
of other research (Bailey et al., 2012; Skinner et al., 2003). Despite 
the high value that participants placed on reproductive autonomy 
and choice, they nearly all struggled with the notion that prenatal 
screening could be interpreted as a negative appraisal of the value of 
people with fragile X syndrome—its expressive potential.
Both participants who supported prenatal screening—as well 
as those who did not—managed this tension by differentiating the 
boundaries between personhood, identity, and fragile X syndrome, 
although they did this in completely different ways. For the five par-
ticipants who supported prenatal screening, being able to conceptu-
ally disentangle people with fragile X syndrome from the pathology 
that caused it became a strategic device to neutralize the threat that 
prenatal screening posed to the value of their affected relatives. By 
viewing screening as targeting, and potentially eradicating, a dis-
ease rather than a person, prenatal screening supporters were able 
to subjugate the distress they felt at supporting a technology that 
could have, at least in theory, been used to prevent the birth of their 
own child.
Participants who did not support prenatal testing, however, or 
were ambivalent toward the technology, also drew on discourses of 
personhood, identity, and genetic conditions to support their posi-
tion, although they did this in an entirely different way. For these 
participants, the very nature of fragile X syndrome, more specifi-
cally, its impact on personality, learning, and behavior, meant that 
the separation of the person from the condition was considered an 
impossibility. For these participants, fragile X was deemed to cre-
ate particular types of people—‘the Lucas of this world’ (Chiara)—who 
were united by their similarity of traits, not only to other people with 
fragile X conditions within their own family, but also across other 
fragile X affected families. As such, it was inconceivable, for these 
participants, that the condition and the person be considered two 
separate entities.
These unique forms of biosociality and kinship identification 
(Featherstone et al., 2006) were interpreted in different ways. For 
some, they were a source of shame and guilt (Jane), for others, they 
formed part of a family legacy that also carried positive attributes 
(Kathryn). Whether they were interpreted positively or negatively 
however, these characterizations nevertheless reinforced the indi-
visible nature of the person and the condition, meaning that prenatal 
screening practices (when used for the purposes of selective termi-
nation) were more closely tied to a negative judgment on the value 
of particular types of people.
Taken together, these findings suggest that the ‘expressivist 
objection’ to prenatal testing and screening may be perceived and 
experienced in different ways across disabilities. While it has long 
been acknowledged that the nature of an impairment (in particular 
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its age of onset and its relative stability over time) has a signifi-
cant impact on the degree to which disabled people incorporate it 
into their identity and sense of self (Bogart et al., 2017; Hoffman-
Andrews et al., 2019), this study suggests that other impairment 
variables, specifically whether the impairment is physical or cogni-
tive in nature, may also impact the degree to which expressivist con-
cerns around genetic screening are experienced, interpreted, and 
responded to. While previous research has demonstrated that the 
higher the degree of perceived integration between self and impair-
ment, the greater the significance of expressivist concerns within re-
productive views and decisions (Boardman & Hale, 2018), this study 
adds that for conditions that affect behavior and personality, the 
blending of personhood with condition results in very particular ex-
periences with expressivist concerns and, consequently, strategies 
of deflection.
4.1 | Conclusions and Practice Implications
Overall, therefore, this study demonstrates the complexity of the 
views of families and adults living with fragile X syndrome toward 
population screening programs and the significance of impairment 
effects in this process. This study highlights the need to consider 
the nature of the impairment in question and its wider social po-
sitioning in terms of stigma when interpreting the responses of 
these families. Conditions that involve learning, behavioral, and 
personality differences have unique impacts compared to those 
that are physical, and for participants in this study, resulted in very 
specific iterations of expressivism, identity, stigma, and repro-
ductive dilemmas, brought to the fore by a discussion of screen-
ing. Tapping into this wealth of expertise and insight possessed 
by families and individuals such as these may be used to better 
understand, anticipate, and address the increasing complexity 
of reproductive decision-making in an age of expansive genomic 
medicine.
4.2 | Strengths and Limitations
This study is strengthened by the range of relationships to fragile X 
conditions within the sample, and the inclusion of people with fragile 
X syndrome and FXTAS themselves. Moreover, the sample had con-
siderable experience with fragile X conditions to draw on, with 13 
of the 19 participants (68%) having two or more affected relatives.
In spite of this, however, the final sample, and methods of re-
cruitment, pose certain limitations.
In the first instance, the sample size was relatively small over-
all, which limits the transferability of the findings. Indeed, perspec-
tives on screening among families living with fragile X conditions are 
multiple and complex, and this study represents a small sample of 
views. However, by focusing on a small sample of participants, this 
analysis was able to achieve depth of analysis that would have been 
precluded by a larger sample size.
Secondly, despite concerted efforts to include people living with 
fragile X conditions, the number who participated in the study was 
also small overall (n = 3). Two participants had fragile X syndrome 
and one had FXTAS. Though snowball sampling was attempted to 
increase numbers, this was ultimately unsuccessful. Given the de-
manding nature of the research topic, however, both in terms of in-
tellectual and emotional complexity, the successful inclusion of two 
people living with fragile X syndrome could ultimately be considered 
a strength of the project.
Thirdly, parents of children newly diagnosed with fragile X 
syndrome were notably under-represented in the sample; 7/11 
parents had children aged 15 or over at the time of interview. 
This may have influenced attitudes to newborn screening as their 
children were diagnosed before 2007, the point at which genetic 
testing became more accessible (Gabis et al., 2018). Indeed, the 
average time to diagnosis for this sample was 4.5 years, longer 
than the average of 3 years reported in the literature (Bailey 
et al., 2009).
Finally, this study is further limited by its reliance on a support 
group and a UK research center mailing list as the means of re-
cruitment, meaning that there was a degree of self-selection to the 
sample.
Despite these limitations, however, the final sample produced a 
rich and diverse dataset, highlighting a range of perspectives and ex-
periences with fragile X syndrome and FMR1-associated conditions.
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